This newsletter presents you the following key sessions:
1. Video-interview with Prof. Ahmad Awada, Md, PhD on update of the Phase 3 CLEOPATRA Trial
2. Adjuvant immunotherapy with MAGE-A3 does not prolong disease free survival in patients with NSCLC
3. Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone
in advanced melanoma
4. The novel NK-1 receptor antagonist rolapitant reduces nausea and vomiting in patients receiving
cisplatin-based chemotherapy
5. Continued bevacizumab improves second-line progression-free survival in women with
bevacizumab pre-treated locally recurrent or metastatic breast cancer
6. High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery in
patients with malignant pleural mesothelioma
